Drug Profile
Research programme: gene-encoded antibody vaccines - SmartPharm Therapeutics/Sorrento Therapeutics
Alternative Names: Gene MAbs SARs-Cov-2Latest Information Update: 04 Sep 2020
Price :
$50
*
At a glance
- Originator SmartPharm Therapeutics; Sorrento Therapeutics
- Class COVID-19 vaccines; DNA vaccines; Monoclonal antibodies; Viral vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Research COVID 2019 infections
Most Recent Events
- 01 Sep 2020 SmartPharm Therapeutics has been acquired by Sorrento Therapeutics
- 23 Mar 2020 SmartPharm Therapeutics and Sorrento Therapeutics agree to co-develop gene-encoded antibody vaccines for COVID-2019 infections (Prevention)
- 23 Mar 2020 Early research in COVID-2019 infections (Prevention) in USA (IM)